Patient P-02005
Metabolic response 62 at the day-84 endpoint (observed).
Responding: response probability 60%, metabolic response 61 today; biology is not blocking the drug.
Drift detected on day 171 (HRV −6 ms, resting HR +4 bpm, nausea / gi symptoms +9, inflammatory load +7); nothing reported yet — the window to act is open.
49 of 61 scheduled doses in the last 60 days are biologically confirmed (80%); 9 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −12 ms.
91% of 284 similar trajectories improved after DT-01; if this one does, discontinuation risk is expected to fall from 35% to ~29%. Losing this patient costs €6k; the intervention costs €45.
- 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- ✓Track each bowel movement today: time, stool form, urgency, overnight waking
- ✓A 15-minute walk after lunch
- 💊Take the dose at the same time relative to your evening meal
- 💊Electrolyte solution, one sachet after any loose stool
Adherence is not the problem.
sleep quality falling under 35 while GI rises
P-02005 is on day 178 of META-24 (MR, baseline S05): response declining, tolerance favorable, GI deteriorating. Over 14 days response moved -6 and GI +8; discontinuation risk is 35%. The state is between basins, heading towards failing, after diverging from the model on day 171.
Butyrate capacity 66/100, diversity 3.6, intermediate metabolizer. Pushing it down: Enterococcus faecium 5.484% (LPS load) (-29.8), Enterobacteriaceae elevated (-16.9), H2S production above band (-15.2). Pulling it up: Protein (supports) (+29.5), Butyrate producers intact (+17.1). From the daily log: protein -5.6 GI next day.
No action has been tried yet.
Next: DT-01 — 91% of 284 similar trajectories improved, 61% probability here. This would be contradicted by a further GI rise within the onset window or falling adherence.
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and events- Day 0 META-24 started — Baseline state S05
- Day 171 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 171.
- Inflammatory activity+11
- GI instability+8
- Nutritional resilience-5
- Treatment adherence+5
- Toxicity+3
What helped?
No interventions yet.
- 284 similar trajectories
- 91% showed improvement
- median effect visible after 5 days
Daily trackers
Asset settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Heading towards failing · 50 from the failing basin, 38 from restoration.
- DT-01 Dosing / Timing Recommendation91% improved among 11 similar · onset 5 d · confidence 54%
- HY-01 Hydration Protocol67% improved among 12 similar · onset 4 d · confidence 54%
- NP-02 Dietary Support Protocol67% improved among 6 similar · onset 10 d · confidence 54%
- More proteinGI -5.6 next day on high-intake days · n 18
- Nothing clearly counter-productive in the record.
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.6supporter · 95%
- Simple carbohydrates-1.9no signal · 43%
- Insoluble fibre+1.4no signal · 23%
- Alcohol-0.4no signal · 15%
- Ultra-processed food-0.2no signal · 15%
- Dietary fat load+0.1no signal · 15%
DeepGene damage signature
The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.
- 3 opportunists above range: Klebsiella pneumoniae, Enterococcus faecium, Clostridioides difficile
- 2 keystone species absent
- 4 resistance genes
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑25
- BloodInflammatory load index 44
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
- HRV
- 64 ms
- Sleep
- 6.7 h
- Steps
- 5,443
- Resting HR
- 63 bpm
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02390 | 36% | S12 | AD-05 | no change | 58 |
| P-02616 | 34% | S01 | AD-05 | improved | 65 |
| P-02627 | 34% | S11 | AD-05 | improved | 59 |
| P-02516 | 37% | S17 | BR-03 | improved | 55 |
| P-02135 | 35% | S06 | BR-03 | improved | 70 |
| P-02129 | 34% | S08 | BR-03 | improved | 59 |
| P-02167 | 31% | S18 | BR-03 | no change | 66 |
| P-02365 | 40% | S11 | DT-01 | no change | 52 |
| P-02122 | 35% | S12 | DT-01 | improved | 53 |
| P-02106 | 32% | S19 | DT-01 | improved | 50 |
| P-02287 | 32% | S05 | DT-01 | improved | 53 |
| P-02494 | 32% | S01 | DT-01 | improved | 66 |